Go Back
Live
Upcoming Events
Relapse Refractory Hodgkin lymphoma [slides 2023]
Are there any specific patient subgroups who may benefit more or less from TTFields treatment?
What are the implications of the LUNAR trial findings for clinical practice?
Pacritinib: Anemia Mechanisms in MPNs -NFKB/ACVR1- [2023 SLIDES]
MRD: Revolutionizing Lymphoma Care - [2023 SLIDES]
What were the key findings of the LUNAR trial? - Ticiana Leal, MD
How do tumor treating fields (TTFields) work? - Ticiana Leal MD
Myeloproliferative Neoplasms: WHO/ICC Systems - [2023 SLIDES]
Follicular Lymphoma: Treatment and Quality of Life-[2023 SLIDES]
Tyrosine Kinase Inhibitors in Mastocytosis-[2023 SLIDES]
Genomic Profiling and Strategies for Blood Cancer- [2023 SLIDES]
Myeloid Neoplasms with Eosinophilia and TK Fusion Genes [Slides] 2023
Diffuse Large B Cell Lymphoma-What is best for risk prediction and treatment? [2023 Slides].
Checkmate 227 Reveals Six-Year Survival Advantages of Nivolumab + Ipilimumab in mNSCLC
FLAURA2: Should this Positive Trial Change Practice for EGFRm+ NSCLC
Akadeum: What is a T Cell Activation & Expansion Kit?
TTFields Phase 3 LUNAR Trial Results in Metastatic NSCLC - Ticiana Leal, MD
What is the significance OneOncology's pathways?
irAEs and TRBV polymorphisms - Interview with Timothy Looney, PhD
Cancer Immunotherapy Advances: Jill O’Donnell - Tormey, PhD
TIBSOVO's Potential: Susan Pandya, MD, on FDA Priority Review for IDH1-Mutated MDS
Lonsurf: FDA Approval with Bevacizumab - Marwan Fakih, MD
CD8 T cells effectively kill cancer cells - Joshua Brody, MD
Axatilimab in Chronic Graft-Versus-Host Disease AGAVE 201 Results.